World renowned cancer genomic scientist Dr. Lynda Chin is the founder several cancer therapeutics, AI and biomarker companies. A hugely respected expert in her field, she has spoke at over 300 national and international conferences and has co-authored and authored more than 200 peer-reviewed publications. She has conducted ground breaking research in the areas of personalized medicine, functional genomics, human cancers and cancer genomics and was a previously a professor at Harvard Medical School. Outside of her laboratory, she has held several leadership positions on U.S. project The Cancer Genome Atlas (TCGA) and has been an active member of the International Cancer Genome Consortium since it began. She created the first Department of Genomic Medicine at MD Anderson Cancer Center in 2011 with a mission to speed up the translation of scientific advances so they could be used by patients outside of academic centers.
Chin was born in China and moved to the USA as a teenager before attending the Albert Einstein College of Medicine. She later began her independent career as a board-certified dermatologist in New York City at her solo practice, and began to pursue her interest in using technology for evidence-based care in community settings. Chin continues to investigate the benefits of technology-enable care for the most vulnerable members of society, and set up an ecosystem in one of the least affluent communities of South Texas to demonstrate her work.
